Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a major advance in the fields of diabetology, nephrology, and cardiology. The cardiovascular and renal benefits of SGLT2 inhibitors are likely largely independent of their glycaemic effects, and this understanding is central to the use of these a...

Descripción completa

Detalles Bibliográficos
Autores principales: Milder, Tamara Y., Stocker, Sophie L., Day, Richard O., Greenfield, Jerry R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582030/
https://www.ncbi.nlm.nih.gov/pubmed/33095409
http://dx.doi.org/10.1007/s40264-020-01010-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582030/
https://www.ncbi.nlm.nih.gov/pubmed/33095409
http://dx.doi.org/10.1007/s40264-020-01010-6

Ejemplares similares